Depression is one of the most common mental health conditions in the world. It affects how people feel, think, and function in daily life.
While many people improve with antidepressant medications, therapy, or a combination of treatments, some continue to struggle despite trying multiple approaches. This condition is known as treatment-resistant depression, and it can be one of the most difficult forms of depression to treat.
For people living with treatment-resistant depression, symptoms often continue for years. They may experience persistent sadness, loss of interest in activities, low energy, sleep problems, difficulty concentrating, and feelings of hopelessness.
Because existing treatments do not work for everyone, researchers have been searching for new options that might help.
One treatment attracting increasing attention is psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms.
Over the past decade, several carefully controlled clinical trials have suggested that psilocybin may help reduce symptoms of depression, including cases that have not responded to conventional treatments.
While clinical trial results have been encouraging, researchers still know relatively little about how psilocybin performs in everyday medical practice. Clinical trials are conducted under highly controlled conditions and often involve carefully selected participants. Real-world healthcare settings can be very different.
To learn more, researchers in Switzerland examined the medical records of patients who received psilocybin treatment at the Psychiatric University Hospital Zurich. Their goal was to see whether the benefits observed in research studies could also be seen in routine clinical care.
The study included 19 patients with treatment-resistant depression ranging from mild to severe. Each patient received between one and four supervised psilocybin dosing sessions as part of their treatment. The researchers then reviewed changes in depression symptoms before and after treatment.
The results were encouraging. Clinician-rated depression scores dropped substantially after treatment. Before receiving psilocybin, patients had average scores of about 31 out of 60 on a standard depression rating scale. Within 42 days after their final treatment session, the average score had fallen to approximately 20 out of 60.
Patients also reported feeling better themselves. Their self-reported depression scores decreased from an average of 32 out of 63 before treatment to 23 out of 63 afterward. These findings suggest that both healthcare professionals and patients noticed meaningful improvements in depressive symptoms.
The researchers also monitored side effects. Side effects were reported in 30 of the 40 treatment sessions that took place during the study. However, most were relatively mild and temporary. The most commonly reported problems included fatigue, headaches, and tearfulness. Importantly, no serious or long-lasting side effects were documented.
Psilocybin is thought to work differently from traditional antidepressants. Scientists believe it may temporarily increase communication between different parts of the brain, allowing people to break out of rigid patterns of thinking and emotional processing.
Some researchers suggest that this increased brain flexibility may help patients develop new perspectives on their experiences and emotions.
Interest in psychedelic-assisted therapy has grown rapidly in recent years. Studies have investigated psilocybin for depression, anxiety related to serious illness, addiction, and other mental health conditions.
Although early findings have been promising, researchers emphasize that these treatments should only be administered in carefully supervised medical settings.
The Swiss study provides important evidence because it reflects what may happen in routine clinical practice rather than in highly controlled research environments. The findings suggest that the benefits seen in clinical trials may translate into real-world healthcare settings.
However, the researchers caution that the study has several important limitations. The sample included only 19 patients, making it difficult to know whether the results would apply to larger populations.
There was also no comparison group receiving a placebo or alternative treatment. In addition, patients were followed for only a short period, so it remains unclear how long the improvements lasted.
If you care about depression, please read studies about how dairy foods may influence depression risk, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies that ultra-processed foods may make you feel depressed, and extra-virgin olive oil could reduce depression symptoms.
The study was published in The Lancet Regional Health—Europe.
Source: Psychiatric University Hospital Zurich.
